Coherus Oncology Inc

CHRSNASDAQ · USD
0.51USD0.00 (-3.73%)
322

Coherus Oncology Inc (CHRS) Expected Move

CHRS expected move through Nov 20, 2026 is 318.6%, with 3 days to expiration. The implied range is -$1.12 to $2.14, based on the previous trading day's options prices.

Read more

Tracking the CHRS expected move helps you see how far Coherus Oncology Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Coherus Oncology Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the CHRS expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For CHRS, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The CHRS expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Coherus Oncology Inc is unlikely to go.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the CHRS expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Coherus Oncology Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about CHRS.

CHRS Price

EARN
EM

Drag chart to pan. Drag axes to zoom.

ExpirationDTEExpected move (USD)Expected move (%)Upper priceLower price
Nov 20, 20263$1.63318.6%$2.14-$1.12
Dec 18, 202631$0.66129.9%$1.17-$0.15
Feb 19, 202794$1.59311.3%$2.10-$1.08
May 21, 2027185$1.01198.5%$1.52-$0.50

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →